Abbvie (ABBV) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie (ABBV) has completed a Phase 1 study testing a new tablet form of ABBV-722 in healthy adults. The official goal was to measure how the drug moves through the body and how eating affects its absorption, data that will guide later trials and help investors gauge the drug’s path through AbbVie’s pipeline.
The study tested oral tablet doses of ABBV-722 given in different settings. The aim was to confirm that the tablet works as expected and to see how a high-fat meal changes drug levels, an important step before wider use.
This was an interventional Phase 1 trial with a simple, non-random setup. All participants received ABBV-722 in sequence under fasted and fed conditions, with no blinding, focusing on basic safety and drug exposure rather than direct treatment benefit.
The study was first submitted on Jan. 15, 2026, marking its formal launch on the registry. The last update on Apr. 22, 2026 signals that key work is finished and the record has been refreshed to show a completed status.
For investors, this update is modest but positive, as completion reduces early development risk around ABBV-722. While details like efficacy and target use are still unclear, progress in AbbVie’s early pipeline can support sentiment versus large peers as they all seek new growth drivers beyond mature franchises.
The ABBV-722 Phase 1 study is now listed as completed and recently updated, with more information available on the ClinicalTrials portal.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.